AUTL · Autolus Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $1.66
Note written ·
Price against the kill line
29.5% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $1.66, on record since 11 November 2026. The shares are down 48.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $1.66, the 200-day average of adjusted closes as of 11 November 2026, which would show the shares leading the S&P 500; fourth-quarter AUCATZYL revenue above the $45.689 million second-quarter figure would also show the case wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 10 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 41.2
- Revenue, change on a year (%)
- +94.6
- Gross margin (%)
- 56.5
- Operating margin (%)
- −105.6
- Net cash, cash less debt ($M)
- 182
- Enterprise value to sales (×)
- 0.9
All filed numbers
What Autolus Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 41.2 | +94.6 | 56.5 | −105.6 |
| first filed | 45.7 | +118.4 | 55.2 | −95.9 |
| first filed | 26.2 | +191.9 | 6.3 | −227.0 |
| first filed | 24.3 | +83655.2 | −4.3 | −298.3 |
| first filed | 21.2 | — | −35.1 | −337.9 |
| first filed | 20.9 | — | −16.8 | −292.6 |
| Pre-tax income ($M) | −55.6 |
| Net income ($M) four quarters: −256 | −55.1 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | 0.0 |
| Operating cash flow ($M) | −176 |
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 248 |
| Debt ($M) secured debt | 66.8 |
| Net cash, cash less debt ($M) | 182 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 38.0 |
| Inventory ($M) | 35.0 |
| Shareholders' equity ($M) | 27.4 |
| Market value ($M) | 312 |
| Enterprise value, market value plus net debt ($M) | 130 |
| Enterprise value to sales (×) | 0.9 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 11.4 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 3.4% of shares outstanding sold short, 5.1 days of average trading to cover, +7.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $16K |
| 12 monthsfrom | $0 | $16K |
The thesis
Autolus Therapeutics' shares are more likely to lag the S&P 500 over the next three months. AUCATZYL sales fell between the second and third quarters, the quarterly loss widened, and the market did not reward a raised revenue outlook. Fourth-quarter sales settle whether Autolus reaches its new 2026 target of at least $150 million.
The rating is Low because the 10 November 2026 report was mixed. Third-quarter AUCATZYL net product revenue was $41.238 million, below the $45.689 million of the second quarter but above the $39.537 million consensus cited by Benzinga. Autolus now expects 2026 revenue "at or exceeding" the $150 million upper end of its earlier $140–150 million range, according to its 10 November 2026 results presentation. The third-quarter net loss was $55.1 million ($0.21 per share), against a $0.18 consensus loss.
The price reflects doubt about the raised outlook. The shares closed at $1.32 on 10 November 2026, the report day, unchanged from the 9 November 2026 close, then fell to $1.24 on 11 November 2026. That close is 51.9% below the 52-week intraday high of $2.58 set on 19 August 2026.
Bullish and bearish views on Autolus Therapeutics plc
The bull case on Autolus Therapeutics plc (AUTL), in brief: full-year revenue outlook moved up. The bear case: quarterly sales fell between quarters.
Bull case
- Full-year revenue outlook moved up. On 10 November 2026 Autolus said 2026 AUCATZYL revenue should reach or exceed $150 million. Nine-month product revenue was $113.1 million against $51.0 million a year earlier, per the third-quarter 10-Q.
- Gross margin held above 55%. Third-quarter gross margin was 57%, against 55% in the second quarter and 44% for the first nine months, per the 10 November 2026 presentation. The company cites a long-term peak gross margin of 65–70%.
- Cash funds operations into 2028. Cash, cash equivalents and marketable securities were $248.4 million at 30 September 2026. Autolus says this, with the $100 million first and second tranches of its Perceptive credit facility, funds operations into the second quarter of 2028.
- The treatment-centre network keeps growing. Autolus listed 90 authorised US treatment centres in its 10 November 2026 presentation, past its goal of more than 80.
- The autoimmune programme has regulatory support. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for obe-cel in lupus and lupus nephritis on 9 September 2026. Longer-term Phase 1 CARLYSLE lupus data shown at ACR Convergence on 10 November 2026 reported clinically significant improvements in SLEDAI-2K disease-activity scores.
Bear case
- Quarterly sales fell between quarters. Third-quarter AUCATZYL revenue of $41.238 million was 9.7% below the second quarter's $45.689 million (company results, 11 August 2026 and 10 November 2026). The stronger second quarter has not repeated.
- The loss widened. The third-quarter net loss was $55.1 million, against $39.1 million in the second quarter, per the 10-Q filed on 10 November 2026 and the 11 August 2026 release. Earnings per share of −$0.21 missed the −$0.18 consensus cited by Benzinga.
- The shares fell after the report. The close dropped from $1.32 on 10 November 2026 to $1.24 on 11 November 2026, close to the 52-week closing low of $1.21 set on 27 March 2026. The three-month price change is −44.4% (adjusted daily closes).
- Warrant shares can add supply. Autolus registered up to 3,500,000 American depositary shares (ADS) for resale on exercise of a Perceptive warrant in a 22 September 2026 prospectus. The 10-Q filed on 10 November 2026 discloses no exercise.
- The share count is large. Autolus had 266,340,330 ordinary shares outstanding on 9 November 2026, per the 10-Q cover. The company issued new-hire inducement grants on 4 November 2026.
Price setup
The last close was $1.24 on 11 November 2026. That is below the 50-day average of $1.74 and below the 200-day average, both from adjusted daily closes as of 11 November 2026. The 50-day average still sits above the 200-day average, so the recent fall has not yet pulled the shorter average below the longer one.
The shares closed at $1.38 on 4 November 2026 and $1.26 on 5 November 2026, and they have stayed between $1.24 and $1.32 since. The level the downside turns on is the 52-week closing low of $1.21 from 27 March 2026. A close under it would put the shares at a new one-year low despite the raised revenue outlook.
The case turns on the 200-day average. The shares have not closed above it since the October decline, and a close back over it would show buyers crediting the higher revenue outlook.
Catalysts ahead
- 17 November 2026: CEO Christian Itin presents at the Jefferies Global Healthcare Conference in London (8:30am US Eastern time). This is the first public management appearance since the third-quarter report; comments on fourth-quarter demand and the at-least-$150 million 2026 outlook test the revenue case.
- 12 December 2026: American Society of Hematology annual meeting begins (runs to 15 December 2026). Autolus plans additional ROCCA real-world AUCATZYL data and initial Phase 1 AUTO8 data in AL amyloidosis, which test the pipeline beyond the marketed product.
- ~March 2027 (est.): Fourth-quarter and full-year 2026 results. Full-year AUCATZYL revenue against the at-least-$150 million outlook, and fourth-quarter sales against the third quarter's $41.238 million, settle whether sales growth has resumed.
What would change the view
A daily close above $1.66, the 200-day average of adjusted closes as of 11 November 2026, which would show the shares leading the S&P 500; fourth-quarter AUCATZYL revenue above the $45.689 million second-quarter figure would also show the case wrong.
What it trades with
Autolus trades mainly on its own AUCATZYL sales figures and on small-cap biotech sentiment more broadly. Its report-day close was unchanged and the decline came the next session, so its own numbers drove the move. Lupus and amyloidosis data from rival CAR-T developers at ACR Convergence and the American Society of Hematology meeting affect how the market values the pipeline beyond AUCATZYL.
The evidence, claim by claim (8)
- Third-quarter 2026 AUCATZYL net product revenue was $41.238 million, against $21.1 million a year earlier and $45.689 million in the second quarter of 2026. Autolus Q3 2026 Form 10-Q and Q2 2026 results release · as of
- Autolus expects 2026 AUCATZYL net product revenue at or exceeding the $150 million upper end of its prior $140–150 million range. Autolus Q3 2026 results presentation, Form 8-K exhibit · as of
- Third-quarter 2026 net loss was $55.1 million, or $0.21 per share, against a $0.18 consensus loss; revenue beat a $39.537 million consensus. Autolus Q3 2026 Form 10-Q; Benzinga · as of
- Third-quarter 2026 gross margin was 57%; gross margin for the first nine months of 2026 was 44%. Autolus Q3 2026 results presentation, Form 8-K exhibit · as of
- Cash, cash equivalents and marketable securities were $248.4 million at 30 September 2026; the company guides that this, with $100 million of credit-facility tranches, funds operations into Q2 2028. Autolus Q3 2026 Form 10-Q and results presentation · as of
- Nine-month 2026 product revenue was $113.1 million, against $51.0 million in the first nine months of 2025. Autolus Q3 2026 Form 10-Q · as of
- Autolus had 90 authorised US treatment centres for AUCATZYL; the FDA granted RMAT designation for obe-cel in lupus and lupus nephritis on 9 September 2026. Autolus Q3 2026 results presentation · as of
- Longer-term CARLYSLE Phase 1 lupus data presented at ACR Convergence showed clinically significant improvements in SLEDAI-2K scores. Autolus announcement, ACR Convergence 2026 · as of
Sources
- Autolus Therapeutics plc - Form 8-K - FY2026 · sec.gov ·
- Autolus Therapeutics plc - Form 10-Q - FY2026 · sec.gov
- Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference · finviz.com ·
- Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · autolus.gcs-web.com
Related · shared themes
AMGN
Amgen
Amgen is modestly more likely than not to beat the S&P 500 over three months because Repatha, Evenity and newer drugs are outgrowing…
DCTH
Delcath Systems
Delcath Systems' shares are more likely than not to beat the S&P 500 after third-quarter revenue of $35.1 million lifted 2026 guidance to…
REPL
Replimune Group
Replimune's melanoma drug TUDRIQEV, first delivered on 6 October 2026, gives the shares a modest edge over the S&P 500 as early prescribing…
TGTX
TG Therapeutics
TG Therapeutics' beat-and-raise on 9 November 2026 lifted its 2026 US BRIUMVI guide to $915–920 million, making the shares modestly likely…
See also · stocks to watch